RedHill Biopharma Ltd. (RDHL)

2.8800 +0.6000 (+26.32%) At close: 04:00PM EST

RedHill Biopharma Ltd.

21 Ha’arba’a Street
Tel Aviv 6473921
Israel
972 3 541 3131
https://www.redhillbio.com

Sector(s): Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Full-time employees: 113

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Dror Ben-Asher	Co-Founder, CEO & Director	734.59k	N/A	1966
Mr. Gilead Raday MPhil, MSc	Chief Operating Officer	445.38k	N/A	1975
Mr. Adi Frish	Chief Corporate & Business Development Officer	419.5k	N/A	1970
Mr. Rick D. Scruggs	Chief Commercial Officer, President of RedHill Biopharma Inc. & Director	607.05k	N/A	1960
Mr. Razi Ingber	Chief Financial Officer	N/A	N/A	1984
Ms. Alexandra Okmian	Senior Business Development & Investor Relations Manager	N/A	N/A	N/A
Dr. Reza Fathi Ph.D.	Senior Vice President of Research & Development	299.29k	N/A	1955
Mr. Guy Goldberg	Chief Business Officer	338.13k	N/A	1976
Dr. June S. Almenoff FACP, M.D., Ph.D.	Chief Medical Officer	N/A	N/A	1957
Ms. Patricia Anderson B.Sc. RAC	Senior Vice President of Regulatory Affairs	N/A	N/A	N/A

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its clinical late-stage investigational development programs include RHB-204, which is in Phase 3 study for pulmonary nontuberculous mycobacteria infections; opaganib (Yeliva), an SK2 selective inhibitor, which has completed Phase 2 study to treat patients with SARS-CoV-2 severe COVID-19 pneumonia, in Phase 2 study to treat advanced unresectable cholangiocarcinoma, and in investigator-sponsored Phase 2 study to treat prostate cancer; RHB-107, which is in Phase 2/3 study to treat outpatients infected with COVID-19 disease, and preclinical evaluation study to treat advanced unresectable cholangiocarcinoma, as well as has completed Phase 2 study to treat gastrointestinal and other solid tumors; and RHB-104, which is in Phase 3 studies for Crohn's disease; RHB-102 (Bekinda) that is in Phase 3 studies for acute gastroenteritis and gastritis. RedHill Biopharma Ltd. was incorporated in 2009 and is headquartered in Tel Aviv, Israel.

Corporate governance

RedHill Biopharma Ltd.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.